Rusan Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
- Paid Up Capital ₹ 4.84 Cr
- Company Age 30 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 259.97 Cr
- Satisfied Charges ₹ 80.83 Cr
- Revenue Growth 0.17%
- Profit Growth -33.95%
- Ebitda -20.66%
- Net Worth 18.29%
- Total Assets 18.81%
About Rusan Pharma
Rusan Pharma Limited (RPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 15 March 1994 and has a history of 30 years and ten months. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Rusan Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.84 Cr.
The company currently has active open charges totaling ₹259.97 Cr. The company has closed loans amounting to ₹80.83 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kunal Saxena, Aakarsh Saxena, Sandeep Verma, and Two other members serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24230MH1994PLC077069
-
Company No.
077069
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
15 Mar 1994
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
What products or services does Rusan Pharma Limited offer?
Rusan Pharma Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antifungal Injection, Tablet & Syrup, Common Disease Medicines, Anti Smoking Drugs, Specialty Supplements, Antioxidants, Popular Category, Bone & Joint Care, Health Conditions, Smoking Cessation.
Who are the key members and board of directors at Rusan Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kunal Saxena
|
Managing Director | 05-Apr-2012 | Current |
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Sandeep Verma
|
Director | 20-Mar-2023 | Current |
|
Aakarsh Saxena
|
Whole-Time Director | 10-Feb-2016 | Current |
|
Balasaheb Patil
|
Whole-Time Director | 17-Oct-2012 | Current |
|
Navin Sexena
|
Director | 15-Mar-1994 | Current |
Financial Performance of Rusan Pharma.
Rusan Pharma Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 0.17% increase. The company also saw a substantial fall in profitability, with a 33.95% decrease in profit. The company's net worth Soared by an impressive increase of 18.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rusan Pharma?
In 2023, Rusan Pharma had a promoter holding of 99.99% and a public holding of 0.01%. The company had 1 Subsidiary and 6 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Quantys Clinical Private LimitedKunal Saxena and Navin Sexena are mutual person
-
Navin Saxena Research And Technology Private LimitedKunal Saxena, Aakarsh Saxena and 1 more are mutual person
-
Navicare Pharma Private LimitedKunal Saxena and Navin Sexena are mutual person
-
Rusan Health Care Private LimitedKunal Saxena, Balasaheb Patil and 1 more are mutual person
-
Tuscany Holdings Private Limited
Kunal Saxena and Navin Sexena are mutual person
-
Iitk Foundation For Medical Research And TechnologySandeep Verma is a mutual person
Charges (Loans)
₹259.97 Cr
₹80.83 Cr
Charges Breakdown by Lending Institutions
- Canara Bank : 169.13 Cr
- Others : 52.50 Cr
- State Bank Of India : 38.34 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Dec 2022 | Others | ₹10.00 Cr | Open |
| 27 Jul 2022 | Others | ₹10.00 Cr | Open |
| 31 Aug 2021 | Canara Bank | ₹75.00 Cr | Open |
| 29 Sep 2020 | Canara Bank | ₹16.50 Cr | Open |
| 23 May 2020 | Others | ₹16.50 Cr | Open |
How Many Employees Work at Rusan Pharma?
Rusan Pharma has a workforce of 656 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rusan Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rusan Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
